Search This Blog

Wednesday, May 6, 2026

Taysha reaffirms FDA alignment and BLA submission pathway for Rett gene therapy TSHA-102

 


  • First-quarter 2026 results include a $42.4 million net loss and higher R&D spending.
  • Ended the quarter with $276.6 million in cash, providing operational runway into 2028.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)